Clinical Trial Software Test Automation: Faster Releases Without Risking Data Integrity

Sometimes, the biggest obstacle to releasing a new feature in clinical trial software has little to do with the feature itself. It’s the same regression checks being repeated by hand, defects that keep coming back, or the time spent making sure nothing else has broken along the way.

And while all that work matters, it doesn’t necessarily have to keep taking up so much engineering time. The question is knowing what to change, and when.

When is automation worth the investment? When are recurring defects a sign of a deeper problem? And when is the testing process itself what’s holding up a release?

Drawing on our work with clinical technology companies, we look at where these problems tend to come from and how you can address them.

When release pressure creates quality and data-integrity risk

Clinical platforms rely on study-specific configurations, calculations, and integrations, often with dependencies that aren’t immediately obvious. A change in one place can affect data capture, transfers, or audit trails elsewhere.

The less visibility teams have into dependencies, the harder it becomes to determine what might need retesting.

Small changes, big consequences: the issue with change-impact analysis and test design

A change that works for one study configuration may break another, which multiplies the scenarios to test.

The fallback is often regression testing. While it does provide a certain degree of protection, it also takes a lot of engineering time, not to mention that it can still easily miss issues between systems.

And that’s exactly the issue: teams that can’t confidently judge the impact of a change may spend more time testing without necessarily improving their chances of catching the most consequential defects.

AI features add another consideration: even when the application, integrations, and data transfers work correctly, model outputs may still be inaccurate or inconsistent, and they need a whole separate level of evaluation.

Of course, not every bug puts trial data at risk. A reminder that doesn’t go out on time is a different problem from an incorrect assessment score. What matters is knowing which failures could have serious consequences and focusing testing efforts there.

When defect work crowds out development

Catching defects is one thing; having to fix the same kinds of problems release after release is another, especially when bug fixes start taking up more time than actual development.

Sometimes it’s the architecture or accumulated technical debt. Other times, the problem lies in how teams share ownership, review changes, or test their work.

Take THREAD, a clinical research software provider that, at one point, was spending 80% of their engineering resources on defect handling.

That’s roughly four hours spent reacting to problems for every hour available for everything else.

The issue wasn’t that THREAD’s developers didn’t know how to fix bugs. The company had development spread across multiple vendors, time zones, and teams, all working a little differently. With so many handoffs, it was easy to patch up an issue without ever even touching the thing that caused it.

Rather than throwing more QA resources at the problem, THREAD needed to focus on changing how the work was organized.

This, combined with root-cause analysis and additional support from KMS, was enough to turn things around: the allocation shifted to 80% focused on innovation, effectively reversing the previous split.

Address the cause, not the symptom: how to get back engineering time

If defects keep coming back, clearing the backlog faster will only get you so far. It’s worth examining the architecture, team structure, and development practices behind those defects; that’s where you’ll usually find the best opportunity to free up engineering capacity for new work.

The same thinking applies to other areas of quality engineering, although the right approach depends on what’s actually taking up the team’s time.

The point is to reduce work that doesn’t need to keep happening.

When repetitive regression consumes capacity

When a platform grows, so does the amount of testing that comes with each release. Every new feature, integration, or study-specific configuration adds more and more scenarios to check.

And while testing is necessary, repeating the same checks manually, release after release, can take up a surprising amount of time, leaving little to no room for new development.

Test automation for clinical trial software might seem like the obvious answer, but automated tests also need to be written, maintained, and updated. At some point, all that work can add up and start eating into the very time they’re supposed to save.

There’s also the question of risk. Some checks are worth automating even if they don’t run particularly often, simply because they cover critical calculations or data transfers where errors could have serious consequences.

Knowing where automation pays off: the Greenphire example

Greenphire (now part of Suvoda) builds payment software for clinical trials, and it has been growing quickly for years. Their growth, however, came with a side effect: their in-house engineering team, whose job was to build new features, was spending more and more of its time on production support.

When Greenphire asked us to take on parts of that workload, we started with automated testing.

In the end, we automated more than 200 smoke, regression, and end-to-end tests across two different products.

Being selective with what to automate took the repetitive work off the team’s plate and freed up real time for the features they were hired to build. Simply going in and automating everything wouldn’t have achieved the same result, as it would have meant a lot of extra oversight.

Over a year, our work saves the company roughly 2,600 hours of manual testing, and that result comes from choosing the right checks, not from automating more of them.

When acceptance processes need to scale

In clinical trial software testing, completing the checks is only one part of the job. Teams also need enough evidence to show what passed, what failed, and why the release is ready for approval.

Clario, a global provider of clinical trial technology, was able to save over $1.05 million a year thanks to changes in its testing process.

They managed to reduce both the time spent testing and the number of defects making it into production, all while gaining enough capacity to release software for around six additional studies each month.

Part of the improvement came from moving testing into shorter development cycles and replacing paper records with qTest. Teams could track requirements, test cases, and defects in one place, making it easier to see what was ready for approval without piecing everything together at the end.

For other teams, there’s a useful lesson here: faster regression testing won’t necessarily mean faster releases if the acceptance process is still holding things up.

Clear requirements, traceable test results, and a shared view of outstanding defects can cut down the work needed for sign-off, while keeping the evidence that clinical software releases require.

When AI features need additional quality checks

The examples above concern conventional software testing. AI features need that, plus a separate way to evaluate model behavior.

Unlike conventional software, AI outputs can vary even when everything works as intended. That makes testing more complicated, especially when errors could affect clinical data or decisions.

The exact controls depend on the feature’s intended use and the consequences of failure, but a good starting point is to set what counts as “acceptable performance” before testing begins.

AI evaluation needs representative examples kept separate from development and tuning data, including known failure cases; otherwise, a good score might tell you very little about how the feature will perform in practice.

And since changes to models, prompts, data, or integrations can all affect the results, teams need to re-evaluate after any relevant updates. When a reviewer spends all day looking at confident AI-generated suggestions, it’s easy to start taking them at face value, which means even the human review needs to be tested as a part of the process.

Ultimately, approving an AI feature takes evidence that both the model and the people working with it can perform dependably enough for its intended use.

Which improvements teams should prioritize first

With recurring defects, manual regression, release approvals, and now AI evaluation to consider, there’s quite a bit that clinical technology teams could work on improving, but simply adding more tests, tools, or people, just for the sake of it, doesn’t automatically get you there.

The real first step is to understand which parts of your current process are holding you back.

Looking at these can help you decide where automation makes sense, where better processes could save more time, and which risks deserve closer attention.

As we’ve seen with THREAD, Greenphire, and Clario, recovering engineering capacity often comes down to fixing a specific problem rather than adding more resources to deal with it.

Find out what’s taking up your engineering time

Start with a Testing Maturity Assessment.

Get a clear view of where your clinical platforms sit today and which automation investments will pay back first.